Log in

NASDAQ:EVLO - Evelo Biosciences Stock Price, Forecast & News

-0.11 (-1.84 %)
(As of 02/23/2020 01:37 PM ET)
Today's Range
Now: $5.88
50-Day Range
MA: $5.00
52-Week Range
Now: $5.88
Volume65,224 shs
Average Volume133,019 shs
Market Capitalization$189.45 million
P/E RatioN/A
Dividend YieldN/A
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EVLO



Sales & Book Value

Annual SalesN/A
Book Value$1.87 per share


Net Income$-85,470,000.00


Market Cap$189.45 million
Next Earnings Date5/7/2020 (Estimated)
OptionableNot Optionable

Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences Inc (NASDAQ:EVLO) issued its quarterly earnings results on Thursday, February, 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.05. View Evelo Biosciences' Earnings History.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Evelo Biosciences.

What price target have analysts set for EVLO?

3 analysts have issued 12-month price objectives for Evelo Biosciences' stock. Their forecasts range from $10.00 to $18.00. On average, they anticipate Evelo Biosciences' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price. View Analyst Price Targets for Evelo Biosciences.

What is the consensus analysts' recommendation for Evelo Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evelo Biosciences.

What are Wall Street analysts saying about Evelo Biosciences stock?

Here are some recent quotes from research analysts about Evelo Biosciences stock:
  • 1. According to Zacks Investment Research, "Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts, United States. " (1/8/2020)
  • 2. Chardan Capital analysts commented, "We have previously expressed some concern on the robustness of this mechanism based on cell trafficking numbers in preclinical animal models (see our 29 January 2019 initiation). The new formulation announced today, though, increases potency up to 30-fold in animal studies, according to management, which could substantially enhance the efficacy signals seen in the clinical trials. The change in formulation, we understand, alters the kinetics of delivery and target engagement relative to the initial product." (5/2/2019)

Has Evelo Biosciences been receiving favorable news coverage?

News stories about EVLO stock have trended very negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evelo Biosciences earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Evelo Biosciences.

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the folowing people:
  • Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)
  • Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)
  • Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)
  • Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)
  • Mr. Jonathan Poole, CFO & Treasurer (Age 44)

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Who are Evelo Biosciences' major shareholders?

Evelo Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (10.11%), Credit Suisse AG (3.72%), Sectoral Asset Management Inc (1.97%), Mayo Clinic (1.51%), State Street Corp (0.71%) and Geode Capital Management LLC (0.39%). View Institutional Ownership Trends for Evelo Biosciences.

Which institutional investors are selling Evelo Biosciences stock?

EVLO stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, FMR LLC, Charles Schwab Investment Management Inc., Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Evelo Biosciences.

Which institutional investors are buying Evelo Biosciences stock?

EVLO stock was bought by a variety of institutional investors in the last quarter, including Mayo Clinic, Credit Suisse AG, Renaissance Technologies LLC, Geode Capital Management LLC, State Street Corp, Barclays PLC and UBS Group AG. View Insider Buying and Selling for Evelo Biosciences.

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $5.88.

How big of a company is Evelo Biosciences?

Evelo Biosciences has a market capitalization of $189.45 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis. Evelo Biosciences employs 75 workers across the globe.View Additional Information About Evelo Biosciences.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is http://www.evelobio.com/.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]

MarketBeat Community Rating for Evelo Biosciences (NASDAQ EVLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Evelo Biosciences and other stocks. Vote "Outperform" if you believe EVLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel